Research feed
Understand the finding first, then explore the evidence. Choose your reading level and sources independently.
Advanced research filters
Dates show original publication, separately from when we added the story. Clinical trials lists registry activity separately. Check collection coverage.
- Animal research· Arthritis & rheumatology (Hoboken, N.J.)
SIRT6 activator MDL-800 reduced osteoarthritis severity in aging mice given monthly injections.
Male mice aged 18 months received weekly intraperitoneal injections of MDL-800 (a SIRT6 activator) or vehicle for 6 months, then were assessed for osteoarthritis at 24 months. MDL-800-treated mice showed less cartilage damage, osteophyte formation, bone sclerosis, and meniscal ossification compared to controls. Mechanistic studies in cultured human chondrocytes showed MDL-800 suppressed catabolic signaling pathways and reduced DNA damage.
Evidence assessment pending · ANIMAL
Read the study · Arthritis & rheumatology (Hoboken, N.J.) ↗ - Animal research· Nature communications
HMGA1-HP1β peptide therapy extended lifespan in a mouse model of Hutchinson-Gilbert progeria syndrome
Researchers studied the HMGA1-HP1β regulatory axis in a mouse model of Hutchinson-Gilford progeria syndrome (LmnaG609G/G609G mice). They developed a peptide called UHP based on the HMGA1-HP1β binding region and found it reduced cellular senescence markers and significantly extended lifespan in the progeria mice, reportedly by stabilizing HP1β and suppressing senescence-associated secretory factors.
Evidence assessment pending · ANIMAL
Read the study · Nature communications ↗